D3 (DRUG DISCOVERY AND DEVELOPMENT)

Business Description

D3 (DRUG DISCOVERY AND DEVELOPMENT) is registered as a business entity on 26 June 2013 (11.6 years ago) structured as a Sole Proprietor with 1 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 53239949L. The business official address is located at 20 Biopolis Way #07-01, Centros, Singapore 138668 with main trading activity as Provide Preclinical And Early Clinical Development Of Drug Discoveries in the primary industry of 72106: Research And Experimental Development On Medical Science using Singapore Dollars - SGD as its default trading currency. The business legal name has undergone change(s) and is previously known as DRUG DISCOVERY AND DEVELOPMENT. The business annual account filing date falls on 26 June and is no longer operational with the status of 'Cancelled (Non-Renewal)'.

In the past 365 days, D3 (DRUG DISCOVERY AND DEVELOPMENT) has received a total of Login to view reported payment review(s). 0 were rated Good and Login to view were rated Poor. Therefore no payment reviews were made recently. The aggregated good payment amount is equivalent to USD 0, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "D" suggest a bad payment culture where settlement with stakeholders is frequently past due. Since the business is no longer active, please take caution if you continue transacting as a counter-party. The lack of an appointed auditor indicates that the business is small sized as it did not meet the regulatory requirements of revenue or assets exceeding SGD 10 million, or has more than 50 employees in the previous two fiscal years.

D3 (DRUG DISCOVERY AND DEVELOPMENT) is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023